Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Rosella Centis and Simon Tiberi.
Rosella Centis
Connection Strength
1.418
Simon Tiberi
  1. COVID-19 and tuberculosis-threats and opportunities. Int J Tuberc Lung Dis. 2020 08 01; 24(8):757-760.
    View in: PubMed
    Score: 0.224
  2. Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. Eur Respir J. 2018 03; 51(3).
    View in: PubMed
    Score: 0.190
  3. Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis? Int J Infect Dis. 2017 12; 65:133-134.
    View in: PubMed
    Score: 0.185
  4. Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. Eur Respir J. 2021 11; 58(5).
    View in: PubMed
    Score: 0.061
  5. Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology. 2021 May-Jun; 27(3):248-256.
    View in: PubMed
    Score: 0.058
  6. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology. 2021 Mar-Apr; 27(2):151-165.
    View in: PubMed
    Score: 0.058
  7. TB and COVID-19 co-infection: rationale and aims of a global study. Int J Tuberc Lung Dis. 2021 01 01; 25(1):78-80.
    View in: PubMed
    Score: 0.058
  8. Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J. 2020 10; 56(4).
    View in: PubMed
    Score: 0.057
  9. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. Emerg Infect Dis. 2020 11; 26(11):2709-2712.
    View in: PubMed
    Score: 0.056
  10. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020 07; 56(1).
    View in: PubMed
    Score: 0.056
  11. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. Eur Respir J. 2018 07; 52(1).
    View in: PubMed
    Score: 0.048
  12. Tuberculosis elimination: where are we now? Eur Respir Rev. 2018 Jun 30; 27(148).
    View in: PubMed
    Score: 0.048
  13. ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update. Eur Respir J. 2018 05; 51(5).
    View in: PubMed
    Score: 0.048
  14. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017 11; 50(5).
    View in: PubMed
    Score: 0.046
  15. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. Emerg Infect Dis. 2017 10; 23(10).
    View in: PubMed
    Score: 0.046
  16. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. J Thorac Dis. 2017 Jul; 9(7):2093-2101.
    View in: PubMed
    Score: 0.045
  17. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017 05; 49(5).
    View in: PubMed
    Score: 0.045
  18. Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. Int J Antimicrob Agents. 2017 Jun; 49(6):688-694.
    View in: PubMed
    Score: 0.044
  19. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. Int J Mol Sci. 2017 Feb 07; 18(2).
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.